Mutation Type Is Not Clinically Useful in Predicting Prognosis in Hypertrophic Cardiomyopathy
Key result
Mutation-specific risk stratification in hypertrophic cardiomyopathy is not clinically useful for predicting prognosis due to contradictory phenotypes and multi-factorial disease expression.
Why the study?
Does mutation type predict prognosis in hypertrophic cardiomyopathy?
Population
Patients with Hypertrophic Cardiomyopathy (HCM)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Mutation-specific stratification should not guide HCM prognosis; leaves open multi-factorial models incorporating modifiers.
Structured PICO
Does mutation type predict prognosis in hypertrophic cardiomyopathy?
P
Population
Patients with Hypertrophic Cardiomyopathy (HCM)
I
Intervention
Mutation-specific risk stratification (e.g., MYH7 and TNNT2 mutations)
O
Outcome
Prognosis / survival
Mutation-specific risk stratification in hypertrophic cardiomyopathy is not currently clinically useful for predicting prognosis.
Cite This Study
Landstrom et al. (2010) conducted a review in Hypertrophic cardiomyopathy (HCM). Mutation-specific risk stratification was evaluated. Mutation-specific risk stratification in hypertrophic cardiomyopathy is not clinically useful for predicting prognosis due to contradictory phenotypes and multi-factorial disease expression.